One of the world's leading research institutes, our scientists are working to advance understanding of biological processes at the molecular level - providing the knowledge needed to solve key problems in human health.

Allergan signs $3.3bn deal with Heptares

Published on 13 April, 2016

Heptares Therapeutics, an LMB spin-out company, announces a deal with Allergan for development of novel treatments for neurological disorders, including Alzheimer’s disease. More…